Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
my problem with all this is that millionaires are not any smarter than any of us.. I have met a lot of dumb accredited investors
Yea, could be that way for a while. Might just tuck this away for a year, seems I make the best returns that way.
Thanks for the insight, keep it up, but mod no..
Oh gosh, look at that, I showed up the day before the run on another one.
Your right I must be just a rookie.
I sold half for a 300% gain, what do I do with the other half a loaf?? make bread?? your advice is always appreciated.
It is a reverse merger play and the new company has scorpion venom and a scorpion farm for pharmaceutical research
This is a runner.. play the play now
ohhhhhhh, counting pennies and watching momentum on a hope stock is not my style........ you will be the first to go with your penny gain and the first to complain if they announce any delays
momentum trader, two week hold for you then you move on?
Apparently you claim to now how government agencies hold to timelines, good for you
oh no not the paid poster theory, here is the deal from my experianced viewpoint.
I hold 300k shares with 100k more on the bid on a gtc. I know this will be a blockbuster and will go parabolic one day, but not in 60 days, if you are prepared for a 6 month hold or do not put a timeline on this thing then you will be fine.
Toe rags are the first to complain when a stock does not hit their perceived timeline... that is all I am saying, which one turns into a basher first.
right, the 30 day turnaround... yup, never takes longer right?
Any day is a little disbelieving Pre-Investigational New Drug (PIND #150335) filing on its lead drug candidate
And when it does not happen for 6 months what are you going to turn into?
Medolife Rx Breaks Ground on Lab Facility and Increases Scorpion Count at First-of-Its-Kind Reservation in the Dominican Republic
BURBANK, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire ? Medolife Rx, Inc. ("Medolife"), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today it has broken ground on its lab facility in the Dominican Republic (DR) as well as increased the quantity of scorpions on the reservation, in preparation for mass production of its pharmaceutical and nutraceutical product lines.
The first-of-its-kind reservation is located in a remote area of the DR and is the ideal climate and terrain to support the healthy cultivation of various scorpions. Certain peptides found in scorpions are used in the formulation of many of the Company’s pharmaceutical and nutraceutical products. The facility, which is currently under construction on the reservation, will be approximately 250 square meters and is expandable as needed in order to meet any increases in demand. It will serve as the Company’s cGMP- and ISO-certified research lab where it will extract the peptides and conduct ongoing research and development on the clinical and wellness applications of Escozine® and other formulations. Its addition will decrease the cost of venom production, enabling the Company to lower the final cost of its products, which will increase margins and the marketability of the products. This expansion will increase the reservation’s capacity ten-fold and the Company’s goal is to be able to produce one million doses of Escozine® per month in the near term.
As the Company furthers its clinical trials and nutraceutical sales of Escozine®, it anticipates that demand will increase exponentially. As such, it has worked with the Ministry of Environment in the DR to secure the appropriate licensing and approvals for the expansion of the reservation and the building of the lab facility. Beyond the use in its own R&D and manufacturing efforts, additional cultivation capacity could be used as an alternative revenue source with scorpion venom being coined as “one the world’s most expensive liquids” by Business Insider.
“Having an integrated supply chain of peptides was not only a strategic decision, but it is also a complete differentiator for our company as a global healthcare player,” said Medolife CEO Dr. Arthur Mikaelian. “There has been significant ongoing research into the potential therapeutic benefits of scorpion venom for years and this facility will position us as essentially the world’s largest cultivator and researcher of these highly specific peptides. With the additional scorpions as well as the integrated lab facility, we will be able to meet the demand for our products while controlling costs and furthering our research and development efforts on the scorpion peptides. We also have the opportunity to monetize any additional serum we extract, creating a whole new revenue opportunity for the company.”
Medolife has been researching Escozine®, a proprietary formulation consisting of small molecule peptides derived from Rhopalurus princeps scorpions, for some time now. The peptides are amplified by the Company’s polarization technology and the Company has clinical trials currently taking place on the product, focusing on treatment of both cancer and COVID-19. In recent months, the Company has announced results from numerous safety and efficacy studies as well as filed its final data set with the US Food and Drug Administration (FDA) as it relates to an Investigational New Drug (IND) filing on Escozine®.
About Medolife Rx
Medolife Rx, Inc. is a global biotechnology company with operations in clinical research, manufacturing, and consumer products. Medolife Rx was created through the merger of Medolife, a private company founded by Dr. Arthur Mikaelian who pioneered the unlaying polarization technology that makes the Company’s portfolio of pharmaceutical and nutraceutical products so effective, and Quanta, Inc., a direct-to-consumer wellness product portfolio company. The Company’s lead clinical development programs include Escozine®, a proprietary formulation consisting of small molecule peptides derived from Rhopalurus princeps scorpions, which is amplified by the Company’s polarization technology and is being researched as a treatment of various indications, including COVID-19 and cancer. The Company has completed preclinical safety and efficacy research on Escozine® and is pursuing product registration and drug approval in various countries, including the United States and throughout Latin America.
Through its subsidiary QuantRx, Medolife manufactures and distributes consumer wellness products in high-impact consumer areas such as pain relief, beauty, and general wellness. QuantRx products are designed using Dr. Mikaelian’s polarization technology, which applies advances in quantum biology to increase the potency of active ingredients. Ultimately, Quanta's mission is to deliver better, more effective ingredients to elevate product efficacy, reduce waste, and facilitate healthier, more sustainable consumption.
Beyond its own clinical and consumer applications, the polarization technology used by Medolife and its subsidiaries has many potential applications. From potentiating bio-ingredients, to producing more-effective carbon-trapping plants, to transformative anti-aging solutions, Medolife has the opportunity to upend how commercial and pharmaceutical products are made and increase their benefits, while decreasing their chemical concentration.
Forward-Looking Statements
Safe Harbor Statement under the U.S. Private Securities Litigation Reform Act of 1995: This release contains statements that are forward-looking in nature which express the beliefs and expectations of management including statements regarding the Company's expected results of operations or liquidity; statements concerning projections, predictions, expectations, estimates or forecasts as to our business, financial and operational results and future economic performance; and statements of management's goals and objectives and other similar expressions concerning matters that are not historical facts. In some cases, you can identify forward-looking statements by terminology such as "anticipate," "estimate," "plan," "project," "continuing," "ongoing," "expect," "we believe," "we intend," "may," "will," "should," "could," and similar expressions. Such statements are based on current plans, estimates and expectations and involve a number of known and unknown risks, uncertainties and other factors that could cause the Company's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. These factors and additional information are discussed in the Company's filings with the Securities and Exchange Commission and statements in this release should be evaluated in light of these important factors. Although we believe that these statements are based upon reasonable assumptions, we cannot guarantee future results. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.
Contacts:
Phil Sands
https://ir.quantrx.com/
818-659-8052
Kyle Porter
medolife@cmwmedia.com
858-264-6600
Source: Quanta, Inc.
Proven reserves per ton times smelter price per ton minus startup costs overhead and infrastructure with factors in play such as mine life equals a market cap of fair value.
Hurry up and wait.
I still have not learned to shut the hell up when I am on the buy side.. another 100k at the ask, gtc...
R/M 's gave me a new zip code this year, up to eyeballs in boxes so concentration has been off on this one. Market cap to potential increase is worth a riverboat gamble.
Launch? Nah, this thing is going to look like a cardiogram on an electric fence..
Can you say gap up?
Great, I see you know how to reach for straws in a blinding hurricane.
Your travel agent thanks you.
Great find, it is a process but the tank has been filled, now we wait for the engine to start.
what was that supposed to mean? That was even too cryptic for me to understand
Well not really, the only thing that changed with this story is COVID delay, just does not suit a traders timeline but for us investors time does not matter....
I AM STARTING TO MISS THE TOE RAG PUMPERS.... can't believe I am even thinking that.
Two of the calling patterns most CEO's receive in a week are
either from retail investors wanting weekly updates and trying to look up the company skirt (and at this point we are not even retail investors of this one)
or
toxic funding sales people promising the best deal out there for the best terms with only 30% discount to market and terms that can never be satisfies
Between all that the CEO has a company to run and has to get on the phone to raise money from accredited investors through the 144 share system. And make sure some employee halfwit does not do something to get him thrown in jail.
it is not easy, been there, done that, got the tee shirt to prove it and would not do it again.
Yup, nothing like waking up to the smell of rotting investors baking in the hot sun.
Big Picture.. keep the share price down until you fold it into the company, then allow the share price to find fair value, then use the share structure to raise money.
Retail investors in the shell are a pain in the ass, they do nothing for the company and provide no support. I have seen CEO's do an ugly reverse split just to get rid of us peons, then a week later do a forward split and carry on.
Best thing we can do is sit and do nothing... and we know that ain't gonna happen. This is a mining play, they take two years to come together sometimes
The problem with us retail investors ( the bottom of the food chain ) is the time element.
Mark has no obligation to do anything, as a matter of fact the longer he waits the more he insures that he has insulated himself from any regulatory issues. I am confident it will happen, I am not so confident in when it will happen.
Being the CEO is a lot like having your cahonas in a vice and the SEC has it's hand on the handle, trust me I have been there
Realistically with the 43-101 behind at least one quarter, maybe even two quarters due to world bug, it will channel in this range for a while. For a company to get onto a legitimate market they need that 43-101 in hand, it is a requirement of the Canadian exchanges and is a prerequisite for raising money. Anyone playing any mining play should consider them a long term hold and turn off the clock on it.
There is nothing negative about the story, it is just not being talked about by a very smart multinational mining company CEO.
Now where do I put the big stink bid? I don't know yet, it will come to me.
BUNM Security Details
Share Structure
Market Cap Market Cap
1,654,804
04/20/2021
Authorized Shares
10,000,000,000
11/28/2007
Outstanding Shares
2,758,006,866
11/09/2007
I am waiting for that gargantuan buy from all the insiders when the share price is at it's bottom. But then, the blood is not on the streets yet.
are those numbers the same on the state SOS?
So, deep within the dark cavern of a third rate message board the messenger has been shot. Ugh, if it takes too long everyone is the enemy.
call them, most will give you the correct count as of close of market yesterday. Some M/M's will not provide that service though. second best is here: https://www.otcmarkets.com/stock/MYRX/security
Watch for the dates to be updated here,(requirement), they are horribly out of date. That is usually the first clue the sinking ship is being repaired.
NO, watch what happens to a market cap this size with a story this big.. this is not my first rodeo sonny!
Market Cap 5,451,054 04/19/2021
your funny, you think a third rate message board run by stock promoters has that much influence on a stock? I live in the world of private placements and millionaire investors.. they have influence.. it is them I want to reach, you take your own approach Mr Clued.
nah I'm a realist... if this story holds true the big money will be getting involved within a couple of months...If that happens then I have found another early riser... final share price I do not care about, it's the story and how it unfolds, the share price will follow.. lets see where we are in one year.
Medolife Rx Announces Pre-Clinical Results on Escozine Showing Synergistic Effect in Killing Cancer Cells When Combined With Chemotherapy Agents
Quanta, Inc.
Tue, April 20, 2021, 5:00 AM
BURBANK, Calif., April 20, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Medolife Rx, Inc. ("Medolife"), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today pre-clinical study results showing that the Company’s lead drug candidate Escozine®, when combined with leading chemotherapy agents such as Cyclophosphamide, Etoposide and Cisplatin, has a synergistic effect in killing leukemia and lymphoma cancer cell lines and cancer cells.
The study, which was performed at one of the leading academic cancer research institutions in the United States, was broken into two objectives:
a. to evaluate the chemosensitization of Escozine® in combination with three different chemotherapy agents for the induction of apoptosis, or cell death, in five cancer cell lines: K-562: Human Chronic Myeloid Leukemia (CML); MEC-1: Human Chronic B Cell Leukemia; NAMALWA: Human Burkitt Lymphoma; RAJI: Human Burkitt Lymphoma, TP53 Wild Type; RAMOS: Human Burkitt Lymphoma, TP53 Mutated
b. to evaluate the chemosensitization of Escozine® in combination with three different chemotherapy agents for the induction of apoptosis, or cell death, in four Chronic Lymphocytic Leukemia (CLL) patients, two at high-risk and two at low-risk levels
The study was designed to determine if Escozine® had a synergistic, additive or antagonistic effect when combined with other chemotherapy agents. The result of both objectives showed that Escozine® had a synergistic effect when combined with the chemotherapy agents, meaning the compounds induce greater apoptosis when given together than the total effects of both compounds alone (the compounds help each other be more effective). The Company considers this result very positive in that its lead drug candidate increased the effectiveness of chemotherapy in killing cancer cells and cancer cell lines. For reference, cell lines are commonly used in in vitro model systems in many drug discovery research programs. They retain most of the genetic properties of the cancer of origin and provide researchers with a source of biological material for experimental purposes.
your just ahead of the herd... lets just hope it's not a herd of lemmings on their way over a cliff.
They take time, if the story is moving forward then volume and share price will follow.
The next step here is to verify the share structure with a market maker, that is a FINRA requirement on reverse merger plays
Waiting for this to be updated and verified
Authorized Shares
60,000,000
06/30/2013
Outstanding Shares
34,479,051
07/12/2013
The formula is right for this company to succeed, lets see if they can execute their game plan. Share price is not my concern, where the company is two years from now is my focus..
I spend way more time researching than I do trading.. buy early, hold long, if the toe rag crowd gets noisy here I just turn off the channel.. wait for it, it's coming.
It's coming, wait for it.. the next pr should set the stage for a run.
yes STHC would have to complete the merger and be fully compliant on the OTC, then when the treasury can support a higher listing it will happen. most of us will be gone long before that happens, that could be a 5 year plan. If it happens at all.
Makes one wonder he might be sitting on an international mining company with rules and regulations pertaining to TSX and NASDAQ requirements... If this CEO was spouting off or blowing smoke I would have been gone long ago.. nah, he's doing it right.. you try being a mining company CEO, it is not easy.
There is some risk here, TSX is sometimes notorious for nit picking financials or issues. But hopefully support staff,(lawyers, accountants) have done their homework.
Final approval of the Acquisition remains subject to TSX-V’s review of the documentation. The Company will provide a further update on the Acquisition once the TSX-V has completed its review of the documentation.